1. Loser: Daiichi Sankyo

Company: Daiichi Sankyo
Symbol: $JP:4568
Beginning Price: 1524 yen
Ending Price: 1254 yen
Loss: 17.72%

If Daiichi Sankyo's top-level management are frustrated, you can't blame them. As 2012 began, the company dispatched a Japanese posse to oversee manufacturing at its troubled Indian subsidiary, Ranbaxy Laboratories. Then, the company announced Ranbaxy's precedent-setting consent decree with the FDA, which included a $500 million charge. That took its toll on the Indian company's bottom line--and, like Ranbaxy's other losses, caused a ripple effect at the parent company the following quarter. Meanwhile, the company's Effient blood thinner failed to best rival Plavix, now generic, in a clinical trial. An oncology partnership with ArQule ($ARQL) hit rocky ground as a lung cancer drug failed a late-stage trial. And as the yen lost ground against the dollar, currency losses helped undercut net income for the first 6 months of its fiscal year. The company's good news--including modest year-over-year sales growth and a new vaccine alliance with GlaxoSmithKline ($GSK)--was capped off by another fiasco at Ranbaxy. The Indian company had to recall its copy of Pfizer's ($PFE) cholesterol drug Lipitor, the drug that had helped redeem Ranbaxy in Daiichi's books, in late November.

For more:
Daiichi Sankyo opens first U.S. manufacturing plant
Ranbaxy CEO to ride out transformation under DOJ oversight

 

1. Loser: Daiichi Sankyo
Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.